Dimensional Fund Advisors LP grew its position in Cascadian Therapeutics, Inc. (NASDAQ:CASC) by 203.7% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 97,880 shares of the biopharmaceutical company’s stock after buying an additional 65,651 shares during the period. Dimensional Fund Advisors LP owned approximately 0.20% of Cascadian Therapeutics worth $364,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the business. State of Wisconsin Investment Board bought a new stake in shares of Cascadian Therapeutics in the second quarter worth approximately $104,000. New York State Common Retirement Fund bought a new stake in shares of Cascadian Therapeutics in the second quarter worth approximately $136,000. BB&T Securities LLC bought a new stake in shares of Cascadian Therapeutics in the second quarter worth approximately $143,000. Rhumbline Advisers bought a new stake in shares of Cascadian Therapeutics in the second quarter worth approximately $143,000. Finally, Bank of America Corp DE grew its stake in shares of Cascadian Therapeutics by 2,316.5% in the first quarter. Bank of America Corp DE now owns 37,528 shares of the biopharmaceutical company’s stock worth $155,000 after acquiring an additional 35,975 shares during the period. 80.35% of the stock is owned by institutional investors and hedge funds.

Shares of Cascadian Therapeutics, Inc. (NASDAQ:CASC) opened at $4.05 on Wednesday. Cascadian Therapeutics, Inc. has a 12-month low of $3.18 and a 12-month high of $6.72.

Cascadian Therapeutics (NASDAQ:CASC) last announced its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.01. During the same quarter in the prior year, the business earned ($0.09) EPS. equities analysts forecast that Cascadian Therapeutics, Inc. will post -1.27 earnings per share for the current year.

A number of brokerages have recently commented on CASC. Zacks Investment Research lowered shares of Cascadian Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, November 14th. Cantor Fitzgerald reiterated a “hold” rating and issued a $4.00 price target on shares of Cascadian Therapeutics in a research note on Monday, September 11th. Barclays began coverage on shares of Cascadian Therapeutics in a research note on Wednesday, September 6th. They issued an “underweight” rating and a $4.00 price target for the company. ValuEngine lowered shares of Cascadian Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. Finally, Cowen restated a “buy” rating on shares of Cascadian Therapeutics in a research report on Wednesday, August 9th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $5.63.

ILLEGAL ACTIVITY NOTICE: This article was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://theolympiareport.com/2017/12/06/cascadian-therapeutics-inc-casc-holdings-lifted-by-dimensional-fund-advisors-lp.html.

About Cascadian Therapeutics

Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.

Institutional Ownership by Quarter for Cascadian Therapeutics (NASDAQ:CASC)

Receive News & Ratings for Cascadian Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.